19th WorldMEN Meeting
  1. Início

Programação

Filtrar atividades
Sala 1
07:45 - 08:00
Welcome

Introduction

Sala 1
08:00 - 08:40
Plenary Session

Effective tools to expand worldwide collaborations. Examples of effective alliances.

08:30 - 08:40
Discussion
Sala 1
08:40 - 10:10
Symposium

Paraganglioma/Pheochromocytoma

08:40 - 08:50
Unmet needs
08:50 - 09:10
Update on genetics of paragangliomas
09:10 - 09:30
Personalized management of pheochromocytomas and paragangliomas
09:30 - 09:50
Systemic treatment of metastatic pheochromocytomas and paragangliomas
09:50 - 10:10
Discussion
Sala 1
10:10 - 10:40
Coffee Break

Poster Discussions

Sala 1
10:40 - 12:20
Symposium

Pituitary

10:40 - 10:50
Unmet needs
10:50 - 11:05
Genetics of familial isolated pituitary tumors
11:05 - 11:20
Genetics of pediatric pituitary tumors
11:20 - 11:35
Consensus guidelines for the diagnosis and management of pituitary adenomas in childhood and adolescence – a summary
11:35 - 11:50
Genetic basis of non-functioning pituitary tumors: Insights into tumorigenesis and progression
11:50 - 12:20
Discussion
Sala 1
12:20 - 13:00
Sponsored Lecture

Lilly | The role of RET inhibitors in the treatment of advanced thyroid cancers

Sala 1
13:00 - 13:30
Break

Poster Discussions

Sala 1
13:30 - 14:30
Oral Presentations

.Oral Presentations

13:30 - 13:40
Thyrosine Kinase Inhibitors for Advanced Medullary Thyroid Cancer: Insights from a Multicenter Cohort
13:40 - 13:45
Discussion
13:45 - 13:55
Comparison of Clinical Features and Outcomes Among Patients with MEN 2A Syndrome and RET Codon 634 Pathogenic Variants
13:55 - 14:00
Discussion
14:00 - 14:10
Mahvash Disease
14:10 - 14:15
Discussion
Sala 1
14:30 - 16:00
Symposium

MEN2 Syndrome

14:30 - 14:40
Unmet needs
14:40 - 15:00
A critical review of the 2015 ATA Risk Stratification of RET mutations and timing for prophylactic thyroidectomy. Time for change?
15:00 - 15:20
Insights from proteomic profiling of medullary thyroid cancer.
15:20 - 15:40
From normal C cell to MTC
15:40 - 16:00
Discussion
Sala 1
16:00 - 16:20
Coffee Break

Poster Discussions

Sala 1
16:20 - 17:10
Panel

New American Thyroid Association Guideline for Advanced Medullary Thyroid Cancer

Sala 1
17:10 - 18:00
Symposium

Advances in Bilateral Macronodular Adrenocortical Disease (BMAD)

17:10 - 17:30
A Global Approach to the Long-Term follow-up of 17 Brazilian Families with Bilateral Macronodular Adrenal Disease
17:30 - 17:50
The role of KDM1A and other genetic alterations associated with BMAD
17:50 - 18:00
Discussion
Sala 1
08:00 - 09:35
Symposium

Parathyroid Diseases

08:00 - 08:15
The FIRMO parathyroid medal
08:15 - 08:30
PHPT - advances in diagnosis and management
08:30 - 08:45
Genetics of parathyroid neoplasia
08:45 - 09:00
Advances in the treatment of post-surgical hypoparathyroidism
09:00 - 09:15
Parathyroid cancer – MD Anderson experience
09:15 - 09:35
Discussion
Sala 1
09:35 - 10:05
Coffee Break

Poster Discussions

Sala 1
10:05 - 11:20
Symposium

Pancreatic Neuroendocrine Tumors

10:05 - 10:15
Unmet needs
10:15 - 10:30
Predicting and preventing PNETs
10:30 - 10:45
Surgical management of PNETs in MEN1
10:45 - 11:00
The role of precision medicine in the management of advanced PNETS
11:00 - 11:20
Discussion
Sala 1
11:20 - 12:20
Symposium

Treatment of Pancreatic Neuroendocrine Tumors – Beyond traditional surgery and targeted therapy

11:20 - 11:35
A new era in management of PNETs
11:35 - 11:50
PNET: Radionuclide therapy - Current experience and perspectives
11:50 - 12:05
Update in liver transplantation for metastatic PNET
12:05 - 12:20
Discussion
Sala 1
12:20 - 13:00
Sponsored Lecture

IPSEN | Neuroendocrine Tumors: challenges and advances in treatment landscape.

Sala 1
13:00 - 13:30
Break

Poster Discussions

Sala 1
13:30 - 14:15
Oral Presentations

Oral Presentations

13:30 - 13:40
Phenotypic Distinctions Between MEN1 Mutation-Positive and -Negative Probands: Insights from a Large Cohort and Development of a Predictive Online Tool
13:40 - 13:45
Discussion
13:45 - 13:55
Methylome profiling of MEN1 assocaited GEP-NETs reveals functional heterogeneity and a β-cell subtype with high GHRH expression
13:55 - 14:00
Discussion
14:00 - 14:10
Multicenter Brazilian Experience with Temozolomide in Aggressive Pituitary Tumors
14:10 - 14:15
Discussion
Sala 1
14:15 - 15:45
Symposium

MEN 1 Syndrome

14:15 - 14:35
Update in genetics of MEN1
14:35 - 14:55
The role of epigenetics in PNET development and as a potential therapeutic target
14:55 - 15:15
Unilateral clearance versus subtotal or total parathyroidectomy
15:15 - 15:45
Discussion
Sala 1
15:45 - 16:15
Coffee Break

Poster Discussions

Sala 1
16:15 - 16:45
Sponsored Lecture

MSD | Targeting HIF pathway in tumors associated to VHL syndrome

Sala 1
16:45 - 17:45
Plenary Session

MEN1 Guidelines

Sala 1
17:45 - 18:00
Meeting Summary and Awards

Perspectives